|
|
|
| home > ict > Spring 2009 |
|
|
 PUBLICATIONS |
International Clinical Trials |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. ICT provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of ICT. |
 |
| |
|
|
|
| The effects of the recession and the prospect of thinning pipelines are major concerns for pharmaceutical companies; Sriram V of Frost & Sullivan discusses the long-term outlook for CROs. |
|
|
| Nicola Murgatroyd at Phlexglobal examines the importance of the role of clinical research associate and looks at the reasons why the industry is facing a shortage of candidates. |
|
|
| The increasing number of clinical trials being performed in developing economies has made high quality translation more important than ever, argues Mimi Maeda-Nye of TJC Global. |
|
|
|
| James Trammel at i3 Statprobe underlines the value of adaptive randomisation, explaining the methods that can be used to guarantee the validity of statistical conclusions. |
|
|
| In the context of the dramatic increase in the number of late-phase clinical trials worldwide, Kate Trainor of PAREXEL International looks at how the right technology can make a major difference in Phases IIIb and IV. |
|
|
| Tim Davis of Exco InTouch reflects on the immense popularity of SMS communication, and explains how text messaging technology can increase recruitment, retention and compliance in clinical trials |
|
|
| A well-integrated laboratory information management system, with the flexibility to work with an adaptive trial design, greatly increases the ability to get specimen handling, testing and reporting 'right first time', says Ed Krasovec of Starlims. |
|
|
|
|
| For clinical research conducted in developing countries, ethical concerns are a particularly salient issue. Harald Schmidt of the Nuffield Council of Bioethics and Peter G Smith of the London School of Hygiene & Tropical Medicine review the 2008 Declaration of Helsinki. |
|
|
|
| In light of the tough economic times, Richard N Williams of INC Research looks at how value can be maximised and drug development accelerated by embracing fresh regulatory initiatives. |
|
|
|
Beata Paluchowska of Omnicare Clinical Research describes how the challenges involved in clinical trials for cancer drugs can be overcome by means of collaboration with oncology communities and experts from different fields. |
|
|
| Jan Vertommon at Capsugel explains how enhanced bioavailability can improve the quality of data obtained from first-in-human clinical trials and evaluates the ways in which this can be achieved. |
|
|
| Nick Charles of Mayo Clinic presents a case study on the benefits of running a collaborative trial for Graves' ophthalmopathy. |
|
|
|
|
| Jeffrey Litwin of ERT Inc looks at the critical role of central core labs in performing thorough ECG analysis. |
|
|
| Nick Townsend of LabWare explains why configurable LIMS with purpose-built modules are an asset for clinical trials, and looks at the options available when choosing a LIMS product. |
|
|
| As the focus of clinical trial activity shifts towards Asia, Robert Scott-Edwards of ICON Central Laboratories investigates the opportunities and challenges in India. |
|
|
| Geraint Thomas at Laminar Medica outlines the factors to consider when developing a passives cooling system which offers protection while meeting all relevant laws, regulations and guidelines. |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally
Sphere Fluidics, a company commercializing single cell analysis systems
underpinned by its patented picodroplet technology, announced today that
it has appointed six new employees and plans to hire four more staff in
its UK and US sites. Rob Treanor and Andrew Campbell join Sphere
Fluidics as Director of Operations and Director of Finance, respectively
alongside new hires to its sales, operations and scientific teams.
These appointments will expand the Company’s commercial capabilities and
facilitate service and support for new and existing Cyto-Mine®
customers in both the UK and US.
More info >> |
|
 |
White Papers |
 |
|
Syringe siliconization
Gerresheimer AG
Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >> |
|
 |
Industry Events |
 |
Multimodal 2019
18-20 June 2019, NEC, Birmingham, UK
Now in its twelfth year, Multimodal is the UK
and Ireland’s premier freight transport, logistics and supply chain
management event. Shippers and cargo owners attend to improve their
businesses; by finding ways of moving their products
more efficiently and by meeting new suppliers.
More info >> |
|
|
